USP22 Facilitates Cervical Cancer Progression via Deubiquitinating and Stabilizing IRAK1 to Activate NF ‐ κB Signaling
The FASEB Journal · 15.11.2026 · 40 (21)
DOI: 10.1096/fj.202603200r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 31.10.2026. Verfasst von Wenjuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Uterine Cervical Neoplasms, NF-kappa B, Ubiquitin Thiolesterase. Die Arbeit nennt 39 Literaturangaben. Gefördert von: | Natural Science Foundation of Fujian Province (Fujian Natural Science Foundation), The Joint Funds For the Innovation of Science and Technology, Fujian Province, The Clinical Research Center for Precision Treatment of Gynecological Malignancies of Fujian Province.
Abstract (Originalsprache)
Cervical cancer remains one of the most commonly diagnosed malignancies among women worldwide. Although USP22 is known to be involved in tumor progression, its specific function in cervical cancer remains unclear. This study explored the biological significance of USP22 and the mechanism by which it regulates cervical cancer progression. Through bioinformatic analysis, we identified that USP22 expression was significantly upregulated in cervical cancer tissues and was associated with proliferative potential. Single‐cell RNA sequencing analysis revealed high USP22 expression in malignant epithelial cells, and USP22 expression was associated with the differentiation potential of cervical cancer cells. Moreover, USP22 deficiency suppressed cervical cancer cell proliferation, triggered cell cycle arrest in G0/G1, accelerated apoptosis, and inhibited migration and invasion. Mechanistically, USP22 bound to and deubiquitinated IRAK1, thereby preventing its proteasomal degradation and maintaining NF‐κB pathway activation. USP22 deficiency significantly suppressed xenograft tumor growth and inhibited expression of the proliferation marker Ki67. Furthermore, IRAK1 overexpression abolished the suppressive effects of USP22 deficiency on cervical cancer cell growth and stemness. Collectively, this study provides evidence that USP22 regulates NF‐κB signaling pathway by deubiquitinating and stabilizing IRAK1, suggesting that the USP22/IRAK1/NF‐κB axis is a promising target for developing novel therapeutic strategies in cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- College of Chemistry, Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, China.
ORCID-Profile: Xingyun Xie
Förderung
- | Natural Science Foundation of Fujian Province (Fujian Natural Science Foundation)
- The Joint Funds For the Innovation of Science and Technology, Fujian Province
- The Clinical Research Center for Precision Treatment of Gynecological Malignancies of Fujian Province
- Natural Science Foundation of Fujian Province
Zitieren
APA
Chen, W., Li, S., Wang, X., Qian, M., Ye, Y., & Xie, X. (2026). USP22 Facilitates Cervical Cancer Progression via Deubiquitinating and Stabilizing IRAK1 to Activate NF ‐ κB Signaling. The FASEB Journal, 40(21). https://doi.org/10.1096/fj.202603200r
Vancouver
Chen W, Li S, Wang X, Qian M, Ye Y, Xie X. USP22 Facilitates Cervical Cancer Progression via Deubiquitinating and Stabilizing IRAK1 to Activate NF ‐ κB Signaling. The FASEB Journal. 2026;40(21). doi:10.1096/fj.202603200r
BibTeX
@article{Chen2026,
author = {Chen, Wenjuan and Li, Siyi and Wang, Xueping and Qian, Mengyuan and Ye, Yuling and Xie, Xingyun},
title = {USP22 Facilitates Cervical Cancer Progression via Deubiquitinating and Stabilizing IRAK1 to Activate NF ‐ κB Signaling},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {21},
doi = {10.1096/fj.202603200r}
}
EUVIMED